Medical Stock Spotlight

May 2012
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
The article presents information related to performance of various stocks of business enterprises related to the health care industry in the U.S. It has been informed that price of stocks of Brunswick, New Jersey-based company Savient Pharma Inc. decreased 46% to 0.85 dollar due to decline in net sales for its key product Krystexxa. It has been informed that price of stocks of Rosetta Genomics Ltd. more than doubled to 5.50 dollar.


Related Articles

  • Lumera extends collaboration with S.C. medical university.  // Medical Device Daily;5/2/2007, Vol. 11 Issue 84, p4 

    The article offers news briefs on the health care industry. Nanotechnology developer Lumera has extended its partnership with the Medical University of South Carolina to develop an antibody array measuring the levels and modifications of patient mitochondrial proteins. Rosetta Genomics has...

  • The Pharmaceutical Market: Israel. Enhanced Strategic Intelligence In A User- Friendly Format.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Research & Markets Ltd. has added the report "The Pharmaceutical Market: Israel" to their offering. The report offers five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators and also offers specialized...

  • Medical Stock Spotlight.  // MondayMorning;4/16/2012, Vol. 20 Issue 16, p1 

    The article offers information on the perfomances of shares of various healthcare companies on NASDAQ Stock Market. Oragenics Inc.'s share gained 70 percent. Shares of Talon Therapeutics Inc. leaped 36 percent, banking on the approval of its anti-leukemia therapy called Marqibo by the U.S....

  • KRYSTEXXA.  // MPR - Urologists' Edition;Fall2010/Winter2011, Vol. 7 Issue 1, pA5 

    The article offers brief information on Krystexxa, a PEGylated uric acid specific enzyme from Savient Pharmaceuticals Inc. which can be used for treatment of chronic gout in adult patients.

  • Financings Roundup.  // BioWorld Today;2/2/2011, Vol. 22 Issue 22, p7 

    The article reports on convertible senior notes priced by Savient Pharmaceuticals Inc.

  • No Sale for Savient: Shares Spiral Downward 44.4%.  // Bioworld Week;11/1/2010, Vol. 18 Issue 44, p3 

    The article reports on the 44.4% decline in Savient Pharmaceuticals Inc.'s shares on October 25, 2010 after its failure to find a buyer.

  • Earnings Roundup.  // BioWorld Today;8/5/2011, Vol. 22 Issue 151, p4 

    The article reports on the net loss posted by Savient Pharmaceuticals Inc. during the second quarter of 2011.

  • Earnings Roundup.  // BioWorld Today;11/4/2011, Vol. 22 Issue 215, p7 

    The article reports on the financial performance of Savient Pharmaceuticals Inc. of East Brunswick, New Jersey for the third quarter of 2011.

  • Boost for Savient as drug gets key code. Kaitwasser, Jared // njbiz;1/16/2012, Vol. 25 Issue 3, p3 

    The article reports that Savient Pharmaceuticals Inc. gained a billing code for its refractory chronic gout drug Krystexxa from the U.S. Centers for Medicare and Medicaid Services.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics